Marksans Pharma announced its audited consolidated financial results for the quarter and financial year ended March 31, 2026, reporting strong growth in revenue and profitability. The company delivered a sharp rise in quarterly earnings, supported by higher income and improved operational performance across its business segments.
Strong Quarterly Revenue Growth
During the fourth quarter of FY26, Marksans Pharma posted total income of ₹891.29 crore, registering a year-on-year increase of 23.1% compared to ₹723.80 crore reported in the corresponding quarter of the previous financial year. On a sequential basis, revenue also witnessed healthy growth, rising 15.1% from ₹774.57 crore recorded in the December 2025 quarter.
The steady rise in income highlights continued momentum in the company’s pharmaceutical business and reflects improved demand across key markets. The quarterly performance also indicates expansion in operational scale during the final quarter of the fiscal year.
Net Profit Surges More Than 64%
Marksans Pharma recorded a significant jump in profitability during Q4 FY26. The company reported a consolidated net profit of ₹149.03 crore for the March 2026 quarter, compared to ₹90.73 crore in the same quarter last year. This represents a year-on-year growth of 64.3%.
On a quarter-on-quarter basis, net profit increased 31.1% from ₹113.69 crore reported in the previous quarter. The sharp rise in earnings reflects stronger operational efficiency and higher business volumes during the reporting period.
Full-Year FY26 Performance Remains Positive
For the complete financial year FY26, Marksans Pharma reported total income of ₹3,033.47 crore, marking a growth of 12.8% over ₹2,689.17 crore recorded in FY25.
Annual net profit stood at ₹420.06 crore, reflecting an increase of 9.79% compared to ₹382.62 crore reported during the previous financial year. The full-year numbers indicate stable growth momentum and continued expansion in the company’s consolidated business performance.
Dividend Recommendation for Shareholders
The Board of Directors has recommended a final dividend of ₹0.90 per equity share with a face value of ₹1 each for FY26. The proposed dividend represents a payout of 90% and remains subject to shareholder approval at the upcoming Annual General Meeting (AGM).
If approved, the dividend amount will be credited or dispatched to eligible shareholders within 30 days from the date of the AGM.
Share Price Movement After Earnings Announcement
Following the announcement of the Q4 FY26 financial results, Marksans Pharma shares witnessed strong buying interest in the market. On May 26, 2026, the stock traded significantly higher during the session.
As of 1:09 PM on the NSE, Marksans Pharma share price was trading at ₹238.62, up 8.34% from the previous closing price.
Summary
Marksans Pharma delivered a strong financial performance in Q4 FY26, supported by healthy revenue growth and a substantial increase in profitability. The company reported over 23% growth in quarterly income and more than 64% rise in net profit on a year-on-year basis. Annual earnings also remained positive, reflecting consistent business expansion throughout FY26. Alongside the earnings announcement, the company recommended a final dividend for shareholders, further strengthening investor focus on the stock. The positive quarterly results also supported strong momentum in the company’s share price during trading on May 26, 2026
Disclaimer:
This article is intended solely for educational and informational purposes. The securities or companies mentioned are provided as examples and should not be considered as recommendations. Nothing contained herein constitutes personal financial advice or investment recommendations. Readers are advised to conduct their own research and consult a qualified financial advisor before making any investment decisions.
Investments in securities markets are subject to market risks. Please read all related documents carefully before investing.
